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Abstract

Author Manuscript

Among people with psychosis, those with a history of cannabis use show better cognitive
performance than those who are cannabis naïve. It is unknown whether this pattern is present in
youth at clinical high risk (CHR) of psychosis. We evaluated relationships between IQ and
cannabis use while controlling for use of other substances known to impact cognition in 678 CHR
and 263 healthy control (HC) participants. IQ was estimated using the Vocabulary and Block
Design subtests of the Wechsler Abbreviated Scale of Intelligence. Drug and alcohol use severity
and frequency were assessed with the Alcohol and Drug Use Scale, and we inquired participants’
age at first use. CHR were further separated into early and late age at onset of cannabis use sub*
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groups, and low-, moderate- and high-frequency sub-groups. No significant differences in IQ
emerged between CHR or HC cannabis users vs. non-users, or between use frequency groups.
CHR late-onset users showed significantly higher IQ than CHR early-onset users. Age at onset of
cannabis use was significantly and positively correlated with IQ in CHR only. Results suggest that
age at onset of cannabis may be a more important factor for IQ than use current use or use
frequency in CHR.

Keywords
age at onset; alcohol; cannabis; IQ; prodrome; schizophrenia

Introduction
Author Manuscript

Cannabis is the most widely used illicit substance in both schizophrenia and in those at
clinical high risk (CHR) of developing psychosis (Addington et al., 2014). Furthermore,
cannabis use severity is associated with greater positive symptoms in CHR (Caspi et al.,
2005; Fusar-Poli et al., 2012; Kuepper et al., 2011; Moore et al., 2007) and epidemiological
data suggest a role for cannabis in the onset of psychosis (Buchy et al., 2015a). Recent
prospective data in CHR individuals have indicated that among lifetime cannabis users,
higher baseline use severity (Buchy et al., in press), frequency (Valmaggia et al., 2014) and
first use before the age of 15 (Arseneault et al., 2002; Valmaggia et al., 2014) are associated
with an increased rate of conversion to psychosis.

Author Manuscript
Author Manuscript

It is well documented that among people diagnosed with a psychotic disorder, those with a
history of cannabis use show better cognitive performance than those who are cannabis
naïve (Potvin et al., 2008; Rabin et al., 2011; Yucel et al., 2012). A recent meta-analysis
(Rabin et al., 2011) excluded studies with patients with a current comorbid diagnosis of drug
abuse and reported a medium effect size (Cohen’s d=0.48) for higher IQ in cannabis-using
patients with schizophrenia compared to non-users. Stratifying patients according to
cannabis use frequency has suggested higher IQ in low- vs. high-frequency users (Leeson et
al., 2012), although another study failed to observe this relationship (Tosato et al., 2013).
Yucel et al.(2012) did not observe differences in IQ in psychosis patients with a lifetime
exposure to cannabis compared to never-users, or in users with an early vs. late age at onset
of cannabis use. Thus there is some evidence that patients with psychosis with a positive
lifetime exposure to cannabis and/or who are current users show higher IQ than abstinent
patients, and that use frequency may associate with IQ. The relationship between IQ and age
at onset of cannabis use in people with psychoses is less clear. No published studies have
characterized IQ in youth at CHR of psychosis who use cannabis compared to those who do
not.
Several explanations have been proposed to explain the higher cognitive abilities in
cannabis-using vs. abstinent patients with schizophrenia. One suggestion is that those who
have used cannabis are less neurodevelopmentally impaired than those who did not (Leeson
et al., 2012; Loberg and Hugdahl, 2009; Schnell et al., 2009). Another explanation is that
early cannabis use may induce psychosis onset in less cognitively vulnerable individuals,

Psychiatry Res. Author manuscript; available in PMC 2016 December 30.

Buchy et al.

Page 3

Author Manuscript

i.e., those with better cognitive capacities, thereby facilitating the onset of psychosis that
may otherwise not have occurred (Yucel et al., 2012). A related suggestion is that the better
cognition in patients who use cannabis may have facilitated their recreational drug use like
in typical adolescents (Ferraro et al., 2013). or that superior social skills enable cannabisusing patients to acquire and sustain a drug habit, which is reflected in their cognition
(Potvin et al., 2008; Solowij and Michie, 2007).

Author Manuscript

When assessing the relationship between cannabis and IQ, it is important to control for the
effects of the consumption of other substances. Tobacco and alcohol are the most frequently
used substances among people with schizophrenia and in CHR than in the general
population (Addington et al., 2014; Buchy et al., in press; de Leon and Diaz, 2005) and have
been associated with neurocognitive function in schizophrenia (Morisano et al., 2013; Wing
et al., 2011; Yip et al., 2009)(Allen et al., 1999; Cantor-Graae et al., 2001; Fowler et al.,
1998; Manning et al., 2009) Stimulant use also has a deleterious effect on cognitive
functions in people diagnosed with a psychotic disorder (Bahorik et al., 2014; Serper et al.,
2000a; Serper et al., 2000b; Smelson et al., 2003; van der Meer et al., 2014), and other
studies have reported elevated neurocognition in people with schizophrenia currently using
cocaine (Bahorik et al., 2014; Benaiges et al., 2013). Therefore, these variables must be
taken into account when interpreting results of the relationship between cannabis use and IQ
across the schizophrenia spectrum.

Author Manuscript

The goal of the present study was to assess the relationship between cannabis use patterns
and IQ in CHR youth, while controlling for any use of other substances known to impact
cognition such as tobacco, alcohol and stimulants, as well as antipsychotic medications. This
cohort offers a unique opportunity to examine these associations prior to the onset of
psychosis, in people with a greater probability of developing a psychotic disorder relative to
the general population, but who do not have potential confounds seen in patient studies such
as lengthy antipsychotic treatment. Based on the literature in schizophrenia, we
hypothesized that: 1) CHR youth using cannabis will have a higher IQ compared to those
who do not; 2) CHR youth with a lifetime exposure to cannabis will have a higher IQ
compared to never-users; and 3) CHR low-frequency cannabis users will have a higher IQ
than CHR high-frequency users. Additionally, we conducted exploratory analyses of IQ in
relation to age at onset of cannabis use in CHR youth, and in CHR separated dichotomously
by early vs. late age at onset of cannabis. We also conducted an exploratory analysis of IQ in
CHR converters vs. non-converters separated by current cannabis use (Y/N).

Methods
Author Manuscript

Participants
Participants were recruited for the second phase of the multi-site North American Prodrome
Longitudinal Study (NAPLS-2) (Addington et al., 2012). The final NAPLS-2 sample
consists of 764 CHR participants and 280 healthy controls (HC). The present paper reports
on the 678 CHR and 263 HC participants in NAPLS 2 who provided baseline IQ data and
completed an assessment on cannabis use. All CHR participants were required to meet the
Criteria of Prodromal Syndromes (COPS) using the Structured Interview for Prodromal-Risk
Syndromes (SIPS) (McGlashan et al., 2010).
Psychiatry Res. Author manuscript; available in PMC 2016 December 30.
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Participants were excluded if they met criteria for any current or lifetime axis I psychotic
disorder, IQ<70, past or current history of a central nervous system disorder or DSM-IV
criteria for a current substance dependence disorder. HC participants were also excluded if
they had a first-degree relative with a current or past psychotic disorder. HC and CHR
participants were not matched for IQ; however, we made every attempt to match groups on
age, sex and parental socioeconomic status. A more detailed description of ascertainment,
inclusion and exclusion criteria, and participant details is provided elsewhere.(Addington et
al., 2012)
Measures
The SIPS and the Scale of Prodromal Symptoms (SOPS) (McGlashan et al., 2010) were
used to assess criteria for a prodromal syndrome and severity of attenuated positive
symptoms.

Author Manuscript

Alcohol and drug use for cannabis, cocaine and amphetamine severity over the last month
was rated using the Alcohol and Drug Use Scale (Drake et al., 1996) as 1=abstinent, 2=use
without impairment, 3=abuse, 4=dependence. Frequency of use was rated as 0=no use,
1=once or twice per month, 2=3–4 times per month, 3=1–2 times per week, 4=3–4 times per
week, or 5=almost daily. Frequency of tobacco use was rated differently as 0=no use,
1=occasionally, 2=less than 10 per day, 3=11–25 per day, 4=more than 25 per day. Based on
commonly used measures and interview questions in the literature (Arseneault et al., 2002;
Caspi et al., 2005; Henquet et al., 2005), we also enquired whether they had ever used
cannabis and the age at first use.

Author Manuscript

IQ was estimated with the Vocabulary and Block Design subtests of the Wechsler
Abbreviated Scale of Intelligence (Wechsler, 1999).
Cannabis groups
First, we separated CHR participants into three groups of users: early-onset (>age 15), lateonset (≥age 15), and cannabis naïve.
Next, CHR individuals were grouped according to baseline cannabis use frequency and
compared on IQ: Abstinent, low-frequency (<5 times per month), moderate-frequency (<5
times per week), and high-frequency users (Daily).

Author Manuscript

Lastly, we separated CHR youth into four sub-groups according to baseline cannabis use and
subsequent conversion vs. non-conversion to psychosis: CHR who converted and were using
cannabis (Converter+Cannabis), CHR who converted and were abstinent (ConverterCannabis), CHR who did not convert and were using cannabis (NonConverter+Cannabis),
and CHR non-converters abstinent from cannabis (NonConverter-Cannabis).
Procedures
All eight NAPLS sites (Emory University, Harvard University/Beth Israel Deaconess
Medical Center, University of Calgary, University of California at Los Angeles, University
of California at San Diego, University of North Carolina at Chapel Hill, Yale University, and
Zucker Hillside Hospital) recruited CHR and HC participants. Raters were experienced
Psychiatry Res. Author manuscript; available in PMC 2016 December 30.
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research clinicians who demonstrated adequate reliability at routine reliability checks. Posttraining agreement on the critical threshold for determining initial eligibility, subsequent
conversion status and prodromal diagnoses based on the SIPS was excellent (kappa=.90).
All testers across sites received training on IQ measures at the beginning of the study under
the supervision of LJS and WS and ongoing within site and across site supervision was
carried out at least a few times every month (Meyer et al., 2014). The Principal Investigator
or clinical psychiatrist or psychologist at each site conducted a comprehensive clinical
assessment to determine if entry criteria were met (Addington et al., 2012). Clinical
assessments that included the AUS/DUS were conducted at baseline. The study protocols
and informed consents were reviewed and approved by the ethical review boards of all eight
NAPLS study sites. The authors assert that all procedures contributing to this work comply
with the ethical standards of the relevant national and institutional committees on human
experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Author Manuscript

Statistical Analysis

Author Manuscript

Chi-square or Fisher’s Exact analyses for categorical variables and t-tests for continuous
variables were used to compare CHR and HC groups on demographic variables and
substance use. T-tests were used to compare participants using cannabis at baseline vs. those
who were abstinent on IQ. Spearman’s correlations were used to evaluate associations of age
at onset of cannabis use with IQ scores. ANCOVAs were then used to determine the
relationship between IQ and cannabis use patterns while controlling statistically for the
effects of confounding variables (demographics, alcohol, tobacco, cocaine and amphetamine
use). Univariate ANOVAs were used to compare IQ in the following groups: 1) early-onset,
late-onset, and naïve, and 2) CHR abstinent, low-frequency, moderate-frequency, and highfrequency. Similarly, ANCOVAs were then used to determine the relationship between IQ
and cannabis use groups while controlling statistically for the effects of confounding
variables (see above). Tukey’s post-hoc tests were used to compare groups where
appropriate. The p-value was set to 0.05/6=0.008 to correct for the number of comparisons
with IQ. Statistical analyses were performed using SPSS 21.0.

Results
Demographics, cannabis use patterns and IQ

Author Manuscript

In the entire sample, males and females did not significantly differ on IQ, t=0.24, p=0.81.
Age and years of education showed small but significant positive correlations with IQ
scores, r=0.11, p=0.001; r=0.18, p<0.001, respectively. Alcohol use was also significantly
correlated with IQ, r=0.20, p<0.001. Tobacco, cocaine and amphetamine use did not
significantly correlate with IQ, r=0.007, p=0.83; r=−0.02, p=0.38; r=0.02, p=0.50,
respectively. In CHR, baseline IQ did not differ in those taking antipsychotics from those not
taking antipsychotics, t=0.92, p=0.36. Therefore, years of education and alcohol use were
entered as covariates in all analyses.
As summarized in Table 1, HC participants were significantly older and had greater years of
education than CHR participants. These groups did not differ on gender or race.
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Table 2 displays cannabis use patterns of the CHR and HC groups. These groups did not
differ on baseline cannabis use frequency, lifetime cannabis exposure, number of current
users, or age at onset of cannabis use. However, CHR participants had significantly higher
baseline cannabis use severity.
HC had significantly higher IQ than CHR participants, t=4.62, p<0.001; M=109.5, SD=14.0
and M=104.5, SD=15.4, respectively.
Relationship between IQ and cannabis use patterns when stratifying by CHR/controls
IQ scores in CHR and HC participants stratified by cannabis use are reported in Table 3.

Author Manuscript

Current use—To test hypothesis 1, we evaluated IQ in CHR and HC cannabis users vs.
non-users at baseline. In CHR participants, IQ was significantly higher among those who
were using cannabis compared with those who were not, t=2.82, p=0.005. In contrast, in HC
participants, there was no statistically significant difference in IQ scores between those who
were or were not using cannabis, t=0.49, p=0.63. An ANCOVA adjusting for years of
education and alcohol use in the CHR group indicated that the group difference in IQ was no
longer significant, F(1,668)=0.53, p=0.47. The result in the HC group remained nonsignificant when adjusting for the same covariates with ANCOVA, F(1,244)=0.49, p=0.48.

Author Manuscript

Lifetime exposure—To test hypothesis 2, we evaluated IQ in CHR and HC with a
positive vs. negative lifetime exposure to cannabis. CHR participants who reported a positive
lifetime exposure had a higher IQ than those who had never used cannabis, t=3.38, p=0.001.
By contrast, HC participants with and without a lifetime exposure to cannabis did not
significantly differ on IQ scores, t=0.60, p=0.55. An ANCOVA adjusting for years of
education and alcohol use in the CHR group indicated that this result was no longer
significant, F(1,668)=0.01, p=0.93. The result in the HC group did not change when
adjusting for the covariates with ANCOVA, F(1,258)=2.00, p=0.16.
Relationship between IQ and cannabis use frequency

Author Manuscript

To test hypothesis 3, we evaluated IQ in CHR participants categorized according to baseline
cannabis use frequency. Twenty (3.0%) admitted to high-frequency use, 27 (4.9%) to
moderate-frequency use, 82 (12.1%) to low-frequency use and 529 (78.0%) were abstinent
(data were missing for one participant). Demographic and clinical characteristics as well as
IQ scores for these groups are presented in Supplemental Table 1. IQ scores are presented in
Table 3. These groups significantly differed in age, education, and SOPS total attenuated
positive symptoms, as well as cannabis, alcohol, tobacco and cocaine use. Thus, these seven
variables were entered as covariates using ANCOVA.
The group effect in the ANCOVA was non-significant, F(3,641)=0.51, p=0.68, indicating
that CHR participants classified according to cannabis use frequency did not differ on IQ.
Relationship between age at cannabis use onset and IQ in CHR
To test exploratory hypothesis 1, we first correlated IQ with age at onset of cannabis use in
CHR participants. Age at onset of cannabis use was significantly and positively correlated
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with IQ scores, r=0.26, p<0.001 (see Figure 1). The correlation between age at onset and IQ
scores was non-significant in the HC group, r=0.16, p=0.08. In CHR, when controlling for
years of education and alcohol use with partial correlation, the result remained significant,
r=0.16, p=0.004. In HC participants, adding the same covariates using partial correlation did
not change the results, r=0.12, p=0.18.
Relationship between IQ and early age of onset of cannabis use

Author Manuscript

To test exploratory hypothesis 2, we evaluated IQ in CHR participants sub-grouped by age at
onset of cannabis use. One-hundred twenty-two (18.0%) CHR participants had an earlyonset, 227 (33.5%) had a late-onset, and 327 (48.2%) were cannabis naïve (data were
missing for two participants). Demographic and clinical information for these three groups
are presented in Supplemental Table 2. These groups significantly differed on age,
education, SOPS total positive symptoms, as well as cannabis, alcohol, tobacco and cocaine
use. Thus, these six variables were entered as covariates using ANCOVA.
When comparing these three CHR sub-groups on IQ, the ANCOVA indicated a significant
main effect of Group, F(3,641)=6.13, p<0.001. Tukey’s post-hoc tests indicated that the lateonset group had significantly higher IQ than the early-onset (p<0.001) and naïve CHR
groups (p=0.002).
IQ in CHR converters vs. non-converters separated by current cannabis use vs. no use

Author Manuscript

To test exploratory hypothesis 3, we evaluated IQ in CHR participants categorized by
current cannabis use vs. no use and subsequent conversion vs. non-conversion to psychosis.
Using this categorization, 23 were in the Converter+Cannabis group, 61 in the ConverterCannabis group, 118 in the Non-converter+Cannabis group and 476 in the Non-converterCannabis group. Demographic and clinical information for these four sub-groups are
presented in Supplemental Table 3. These sub-groups significantly differed on age,
education, and alcohol and tobacco use. Thus, these four variables were entered as
covariates using ANCOVA.
When comparing these four CHR groups on IQ, the ANCOVA indicated a significant main
effect of Group, F(3,661)=2.61, p=0.05. As this effect was at trend level after correction for
multiple comparisons, we conducted post-hoc tests to reveal potential group differences.
Tukey’s post-hoc tests indicated that the Non-converter+Cannabis group had significantly
higher IQ than the Non-converter-Cannabis (p=0.04) and Converter+Cannabis group
(p=0.01).

Author Manuscript

Discussion
The aim of the current work was to evaluate IQ in relation to patterns of cannabis use in a
large CHR sample while controlling statistically for confounding demographic variables and
use of other substances that are known to alter cognition. Results indicated that although
both CHR participants with a positive lifetime exposure to cannabis use and CHR current
cannabis users showed higher IQ than CHR participants who were abstinent, these effects
were confounded by age and other substance use. Thus, hypotheses 1 and 2 were not
supported. Hypothesis 3 also received little support as CHR participants classified according
Psychiatry Res. Author manuscript; available in PMC 2016 December 30.
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to cannabis use frequency did not differ on IQ. On the other hand, our exploratory analysis
indicated that in CHR participants, age at onset of cannabis use was significantly and
positively correlated with IQ, and CHR participants with early-onset cannabis use (i.e.,
before age 15) and cannabis naïve CHR participants showed significantly lower IQ than
CHR late-onset users (at or after age 15). Both effects survived when removing variance due
to age and use of other substances, suggesting age at first use of cannabis may be a more
important factor for IQ than use severity/frequency or lifetime exposure in people who are at
CHR of psychosis.

Author Manuscript
Author Manuscript

CHR and HC participants with a positive lifetime exposure to cannabis use were
indistinguishable on IQ from those who had never used cannabis. Our analysis of current
users vs. non-users also suggested no differences in IQ in either CHR or HC groups. It
should be noted that the positive lifetime exposure variable includes people who have used
only once through people who use daily, thereby creating a heterogeneous group whose data
are unlikely to yield meaningful information on which aspects of cannabis use relate to IQ.
Yucel et al.(2012) also did not observe differences in IQ in their first-episode psychosis
patients with a positive lifetime exposure to cannabis compared to never-users. However,
two recent studies in first-episode psychosis reported higher IQ in patients with a positive
lifetime exposure compared to never-exposed patients (Ferraro et al., 2013; Leeson et al.,
2012), and retrospective data from a large cohort of Swedish conscripts have suggested that
lifetime cannabis exposure and low IQ may have an additive relationship on risk for
developing psychosis (Zammit et al., 2010). That current CHR cannabis users did not differ
from CHR non-users is inconsistent with meta-analytic data in schizophrenia suggesting
superior cognitive functioning in cannabis-using patients compared to non-using patients
(Rabin et al., 2011). Our CHR sample had very few observations for “abuse” (n=22) or
“dependence” (n=2), and analyses of samples with higher proportions of CHR youth with
higher use severities may help clarify whether use severity is associated with IQ in this
population. In light of our result, hypotheses that patients with schizophrenia who use
cannabis are less neurodevelopmentally impaired than patients who did not use cannabis
(Leeson et al., 2012; Loberg and Hugdahl, 2009; Schnell et al., 2009) may not extend to the
CHR phenotype.

Author Manuscript

Categorizing CHR participants according to patterns of cannabis use frequency yielded no
indication that low use frequencies were a differentiating factor for IQ in our sample.
Although no studies have examined such relations in CHR individuals, one study in
schizophrenia has reported higher premorbid IQ in low- compared to high-frequency users
(Leeson et al., 2012), although another study failed to observe this relationship (Yucel et al.,
2012). Our CHR sample had very few observations for moderate- and high-frequency users
(n=27 and n=22, respectfully), and samples with higher representation in these categories
may clarify whether an association between use frequency and IQ is seen in CHR youth. Our
data do not provide support for the hypothesis that the neuroprotective properties of cannabis
use accounts for observed relations between low frequency cannabis use and a higher IQ in
schizophrenia (Jockers-Scherubl et al., 2007).
Perhaps the most novel result from our analyses is the significant correlation that emerged
between IQ and age at onset of cannabis use in our CHR sample. This result was not
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observed in HC participants, suggesting a specific effect that is unique to the CHR status. A
younger age at onset is now emerging as an important environmental risk factor in CHR
youth, with findings suggesting that younger age at first usage confers greater risk for
conversion to psychosis (Valmaggia et al., 2014), an earlier age at onset of prodromal and
psychotic symptoms (Leeson et al., 2012), as well as altered brain activation patterns (Buchy
et al., 2015b) and white matter microstructure (Dekker et al., 2010). That age at onset of
cannabis use had a positive and linear association with IQ suggests that an older age at first
use may be a protective factor for a higher IQ in CHR youth. Alternatively, a higher IQ may
lead CHR individuals to delay the onset of their cannabis use during adolescence.
Interestingly, this effect extended to CHR youth dichotomized into early- vs. late-onset
groups, suggesting that first use before age 15 shares a particularly negative relationship
with IQ in our sample. In concert, these results suggest that IQ is associated with the age of
exposure to cannabis in a linear fashion and there may be a specific interaction with IQ
when exposure occurs during a sensitive period in development. This result also has
implications for current theories of cannabis use and IQ in schizophrenia. For instance, these
older individuals may form a subgroup of higher intellectually functioning individuals who
may also be less neurodevelopmentally impaired (Leeson et al., 2012; Loberg and Hugdahl,
2009; Schnell et al., 2009) and/or have higher social functioning than CHR individuals with
an earlier age at onset (Ferraro et al., 2013).

Author Manuscript

Our analysis of CHR converters vs. non-converters sub-grouped by current cannabis use vs.
no-use revealed some interesting findings. First, non-converters using cannabis showed
higher IQ than non-converters abstinent from cannabis. This result is consistent with
findings in people with schizophrenia (Yucel et al., 2012) and suggests that this well
documented effect extends to the CHR population, thus providing support for accounts
holding that those using cannabis are less neurodevelopmentally impaired than those who
are not (Leeson et al., 2012; Loberg and Hugdahl, 2009; Schnell et al., 2009), and that
cannabis users have less premorbid cognitive impairment than those who are abstinent (Joyal
et al., 2003; Rodriguez-Sanchez et al., 2010; Stirling et al., 2005). Second, non-converters
using cannabis at baseline showed higher IQ than converters using cannabis at baseline. This
finding may suggest that in people at clinical risk for psychosis, a lower IQ may be a risk
factor for conversion, or higher IQ may be a protective factor against conversion (Woodberry
et al., 2010). Converters using cannabis did not differ from abstinent converters. This
negative result is inconsistent with other findings in first-episode psychosis (Ferraro et al.,
2013; Leeson et al., 2012), and the small number of people in these groups may have
rendered this analysis under-powered to detect a significant effect.

Author Manuscript

Limitations include the self-report ascertainment of cannabis use, which may be less reliable
than collection of biologically based specimens such as urine toxicology data. Further,
details on cannabis dosage were not collected and therefore their potential impact on IQ
cannot be determined. Nevertheless, the results provide partial support for findings in
schizophrenia, and extend these results by establishing a link between an older age at onset
of cannabis use and higher IQ in CHR. Future research in CHR samples should examine
individuals’ long-term cannabis use patterns and its covariation with IQ over time.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Correlation between age at onset of cannabis use and IQ in CHR, r=0.26, p<0.001.
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Racial information was missing for two participants.

1

Note. CHR, Clinical High Risk; HC, Healthy Controls; SD, Standard Deviation.

Education (years)

Age (years)

48 (18.3)

103 (15.2)

Black

Latin America/Middle East/White

156 (59.2)

24 (9.2)

52 (7.7)

5 (1.9)

127 (48)

13 (1.9)

288 (42)

Female

136 (52)

Asian

390 (58)

Male

n (%)

n (%)

First Nations

Race1

Sex

HC
n=263

CHR
n=678

<0.001

<0.001

p-value

0.94

0.11

p-value

Demographic and clinical characteristics of the clinical high risk and healthy control groups.
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22 (3.2)
2 (0.3)

Abuse
Dependence
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Use severity3

Tobacco

55 (41.6)
20 (13.4)
26 (18.1)
20 (13.4)
19 (12.8)
1 (0.6)

1–2 × per month

3–4 × per month

1–2 × per week

3–4 × per week
Every day
Missing

Use frequency for current users3

2 (0.8)

116 (17.1)

0 (0.0)

4 (1.5)

9 (3.4)

6 (2.3)

6 (2.3)

18 (6.8)

0 (0.0)

41 (15.6)

538 (79.4)

Abstinent

220 (83.7)

128 (48.7)

Use without impairment

Use severity3

351 (51.8)

Lifetime exposure: Yes

43 (16.3)

n (%)
149 (22.0)

n (%)

15.7 (2.9)

Age first tried2

Current user: Yes

16.2 (2.5)

63.7 (109.5)

41.9 (89.4)

Mean (SD)

Mean (SD)

Number of times used in lifetime1

Cannabis

HC
n=263

CHR
n=678

0.46

0.08

0.39

Fisher’s exact
p-value

4.66

6.71

0.73

0.07

p-value

χ2
3.32

0.11

0.004

p-value

1.62

2.88

t

Statistic

Rates and patterns of cannabis and other drug use over lifetime in clinical high risk and healthy control participants.
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0 (0.0)
0 (0.0)

Abuse
Dependence

0 (0.0)

0 (0.0)

2 (0.8)

261 (99.2)

t

0.19

0.47

0.01

0.04

p-value

Statistic

Measured with the Alcohol and Drug Use Scale.

3

Excludes people who had never used cannabis.

2

Excludes never-users.

1

Abbreviations: CHR = Clinical High Risk, HC = Healthy Control, SD = Standard Deviation

1 (0.1)

Use without impairment

667 (99.9)

0 (0.0)

Abstinent

0 (0.0)

0 (0.0)

Abuse
Dependence

0 (0.0)

1 (0.4)

262 (99.6)
1 (0.1)

Use without impairment

667 (99.3)

13 (1.9)

Abuse
Dependence

Abstinent

3 (1.1)

249 (36.7)

0 (0.0)

126 (47.9)

412 (60.8)

Abstinent

133 (50.6)

2 (0.8)

Use without impairment

Amphetamine

Cocaine

Alcohol

Other drug use

0 (0.0)

5 (0.7)

Missing

0 (0.0)

5 (0.7)

Abuse
Dependence

2 (0.8)

32 (12.2)

136 (20.1)

227 (86.3)

532 (78.5)

Mean (SD)

Mean (SD)
Abstinent
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IQ scores of CHR and healthy control participants stratified by cannabis use patterns.
IQ score
CHR
n=678

HC
n=263

Mean (SD)

Mean (SD)

Yes

107.8 (14.9)

108.4 (15.0)

No

103.7 (15.4)

109.6 (13.8)

Yes

106.5 (14.7)

108.1 (14.1)

No

102.5 (15.9)

109.9 (13.9)

Currently using

Lifetime exposure
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Age first tried
Naïve (n=327)

102.5 (15.9)

Early-onset (n=122)

102.0 (14.2)

Late-onset (n=227)

108.9 (14.4)

--

Frequency
Abstinent (n=529)

103.7 (15.5)

Low-frequency (n=82)

108.6 (14.9)

Moderate-frequency (n=27)

106.9 (15.1)

High-frequency (n=20)

109.3 (13.8)

--

Abbreviations: CHR = Clinical High Risk, HC = Healthy Control, SD = Standard Deviation
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